IMMUNOTHERAPY BRIDGE 2016
Royal Continental Hotel, Naples, Italy
November 30th, 2016
| 09.30 AM | Registration ** |
Session I Immunotherapy Beyond Melanoma
Chairpersons: Alfredo Budillon, Graham Pawelec
| 10.00 AM | What we learned from immunotherapy in melanoma, Paolo A. Ascierto |
| 10.20 AM | Checkpoint inhibitors anti PD1/PDL1 in metastatic NSCLC, Vera Hirsh |
| 10.40 AM | Immunotherapy in recurrent and metastatic head and neck cancer, Lisa Licitra |
| 11.00 AM | Perspectives of Immunotherapy in advanced HCC, Bruno Daniele |
| 11.20 AM | Break ** |
| 11.35 AM | Discussion on the best research studies on Immunotherapy Beyond Melanoma ** |
| 12.35 PM | Symposium: "Future prospects of lung, kidney, and head-and-neck immunotherapy" |
| 01.35 PM | Lunch ** |
Session II - Immunotherapy in Oncology: Data from clinical trials
Chairpersons: Sergio Bracarda, Sabino De Placido
| 02.20 PM | Symposium: Immuno-oncology: a new paradigm in the treatment of cancer Chairperson: Paolo A. Ascierto |
| 03.20 PM | Emerging Role of Immunotherapy in Bladder Cancer, Joseph Kim |
| 03.40 PM | Update on immunotherapy in GU malignancies, Hans Hammers |
| 04.00 PM | Break ** |
| 04.15 PM | Immunotherapy for Breast Cancer: Recent Clinical Trial Results, Rita Nanda |
| 04.35 PM | Immunotherapy in ovarian and endometrial cancer, Sandro Pignata |
| 04.55 PM | Discussion on the best research studies on Immunotherapy in Oncology: data from clinical trials ** |
| 05.55 PM | Conclusions, Paolo A. Ascierto |
ORAL COMMUNICATIONS
November 30th 2016
SESSION I - Immunotherapy beyond melanoma
Chairpersons: Alfredo Budillon, Graham Pawelec
| 11.35 AM | Discussion on the best research studies on Immunotherapy Beyond Melanoma ** |
| 11.35 AM | LOH as Rthe missing instabilityR potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer Melissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Donatello Gasparro, Francesco Leonardi, Enrico Maria Silini, Sebastiano Buti |
| 12.05 AM | Inhibition of tumor growth by combination of metronomic chemotherapy and checkpoint inhibitor with a cancer vaccine Maria Tagliamonte, Annacarmen Petrizzo, Angela Mauriello, Antonio Luciano, Domenica Rea, Antonio Barbieri, Claudio Arra, Piera Maiolino, Marialina Tornesello, Gennaro Ciliberto, Franco M. Buonaguro, Luigi Buonaguro |
SESSION II - Immunotherapy in oncology: data from clinical trials
Chairpersons: Sergio Bracarda, Sabino De Placido
| 04.55 PM | Discussion on the best research studies on Immunotherapy in Oncology: data from clinical trials ** |
| 04.55 PM | PET imaging of the PD-1/PD-L1 checkpoint Michael Hettich, Friederike Braun, Gabriele Niedermann |
| 05.25 PM | Adenosine generation limits the ability of radiation therapy to elicit anti-tumor immunity by hindering recruitment and activation of CD103+ DCs Erik Wennerberg, Aranzazu Mediero, Bruce Cronstein, Silvia Formenti, Sandra Demaria |
** Not included in the CME accredited program
For information please contact info@melanomabridge.org
